BiotechTube

Rosuvastatin 20mg + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Homozygous Familial Hypercholesterolemia (HoFH)

Conditions

Homozygous Familial Hypercholesterolemia (HoFH)

Trial Timeline

Nov 1, 2014 → Jul 1, 2015

NCT ID
NCT02226198

About Rosuvastatin 20mg + Placebo

Rosuvastatin 20mg + Placebo is a phase 3 stage product being developed by AstraZeneca for Homozygous Familial Hypercholesterolemia (HoFH). The current trial status is completed. This product is registered under clinical trial identifier NCT02226198. Target conditions include Homozygous Familial Hypercholesterolemia (HoFH).

What happened to similar drugs?

1 of 16 similar drugs in Homozygous Familial Hypercholesterolemia (HoFH) were approved

Approved (1) Terminated (0) Active (15)
✅evolocumabAmgenApproved
🔄Rosuvastatin 20mgAstraZenecaPhase 3
🔄Inclisiran + PlaceboNovartisPhase 3
🔄Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
🔄InclisiranNovartisPhase 3
🔄Inclisiran + PlaceboNovartisPhase 3
🔄Lumacaftor Plus Ivacaftor Combination + Ivacaftor + PlaceboVertex PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02226198Phase 3Completed

Competing Products

20 competing products in Homozygous Familial Hypercholesterolemia (HoFH)

See all competitors
ProductCompanyStageHype Score
Rosuvastatin 20mgAstraZenecaPhase 3
40
Inclisiran + PlaceboNovartisPhase 3
40
Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
40
InclisiranNovartisPhase 3
44
INC280 + BuparlisibNovartisPhase 1/2
24
Inclisiran + PlaceboNovartisPhase 3
47
Evolocumab + PlaceboAmgenPhase 2/3
38
evolocumabAmgenApproved
43
MBX-8025 50 mg (Dose Escalation Period 1) + MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) + MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)Gilead SciencesPhase 2
35
IBI306 + IBI306Innovent BiologicsPhase 2/3
38
BMS-986504 + [14C]-BMS-986504Bristol Myers SquibbPhase 1
36
Lumacaftor Plus Ivacaftor Combination + Ivacaftor + PlaceboVertex PharmaceuticalsPhase 3
40
Placebo + Lumacaftor Plus Ivacaftor Combination + IvacaftorVertex PharmaceuticalsPhase 3
40
Lumacaftor Plus Ivacaftor Combination + IvacaftorVertex PharmaceuticalsPhase 3
40
Alirocumab + PlaceboSanofiPhase 3
40
AK102 + Statins + EzetimibeAkesoPhase 2
35
EvinacumabRegeneron PharmaceuticalsPhase 3
40
evinacumabRegeneron PharmaceuticalsPhase 3
40
REGN1500 250 mg SC/15 mg/kg IV/450 mg SCRegeneron PharmaceuticalsPhase 2
35
EvinacumabRegeneron PharmaceuticalsPre-clinical
26